8-K: Mural Oncology to be Acquired by XOMA Royalty

Mural Oncology plc has entered into a definitive agreement to be acquired by XOMA Royalty Corporation for a cash consideration of $2.035 to $2.24 per share, following Mural's decision to discontinue all clinical development.

Summary

• Mural Oncology plc (MURA) has entered into a definitive agreement to be acquired by XOMA Royalty Corporation (XOMA) through its wholly-owned subsidiary, XRA 5 Corp. (Sub).
• The acquisition will be implemented via an Irish High Court sanctioned scheme of arrangement, or potentially a Takeover Offer under certain circumstances.
• Mural shareholders are entitled to a base cash price of $2.035 per share.
• An additional cash amount of up to $0.205 per share may be received if Mural's actual closing net cash exceeds the estimated closing net cash of approximately $36.2 million.
• The total consideration per share ranges from $2.035 to $2.24.
• The acquisition, excluding the additional price, values Mural's entire issued and to be issued share capital at approximately $36.2 million.
• The base price represents a 13.1% premium to Mural's closing share price of $1.80 on August 19, 2025, and a 97.6% premium to its undisturbed closing share price of $1.03 on April 14, 2025 (prior to strategic review announcement).
• Mural's Board of Directors unanimously recommends the acquisition, deeming it in the best interests of shareholders.
• The acquisition is expected to close by the end of 2025, subject to shareholder and High Court approvals.
• All outstanding Mural options with an exercise price equal to or greater than the consideration will be cancelled without payment. Other options and restricted stock units will be converted into cash rights.
• Mural will operate its business in the ordinary course consistent with a wind-down of operations and R&D activities until closing.
• XOMA Royalty intends to execute an orderly wind-down of substantially all of Mural's legacy operations post-closing, consolidating corporate functions and disposing of assets.

Sentiment

Score: 7

Explanation: The acquisition provides a clear and relatively swift cash exit for shareholders at a significant premium to the undisturbed share price, especially considering the recent discontinuation of all clinical development programs. While the additional cash component is uncertain, the base offer provides a solid return in a challenging situation.

Positives

• Provides a clear exit strategy and a timely return of value to shareholders in cash, avoiding a potentially protracted voluntary liquidation process.
• The base price of $2.035 per share represents a 13.1% premium over the previous day's closing price and a 97.6% premium over the undisturbed price before the strategic review.
• Potential for an additional cash payment of up to $0.205 per share if net cash exceeds estimates, offering further upside.
• Mural's Board of Directors unanimously approved and recommended the acquisition, indicating strong internal support.
• All Mural directors holding shares (approximately 0.42% of outstanding shares) have entered into irrevocable undertakings to vote in favor of the acquisition.
• XOMA Royalty has confirmed sufficient resources to fund the acquisition.

Negatives

• The additional cash amount of up to $0.205 per share is not guaranteed and depends on Mural's actual closing net cash exceeding the estimated $36.2 million. If not, shareholders only receive the base price.
• All outstanding options to acquire Mural Shares held by Mural Directors with a strike price above the maximum consideration will be cancelled without any payment.
• The acquisition will lead to the delisting of Mural Shares from Nasdaq and deregistration under the Exchange Act, eliminating public trading.
• XOMA Royalty intends to wind down substantially all of Mural's legacy operations, indicating a cessation of Mural's original business activities and potential job losses.
• No assurances are given regarding the continuation of existing compensation and employment benefit arrangements for Mural's employees post-acquisition, except in limited circumstances.
• Mural had previously discontinued all clinical development of its lead drug, nemvaleukin, due to failed trial endpoints, indicating a lack of viable product pipeline.

Risks

• Uncertainties regarding the timing and completion of the Scheme Meeting and Extraordinary General Meeting (EGM).
• Uncertainties regarding the approval of the acquisition by Mural shareholders.
• Possibility that closing conditions for the acquisition may not be satisfied or waived, including failure to receive High Court sanction.
• Risk that ongoing costs to Mural will result in its actual closing net cash not exceeding the estimated closing net cash, meaning no Additional Price Per Share is paid.
• Risks and uncertainties pertaining to Mural's business, including those described in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
• Risks and uncertainties pertaining to XOMA Royalty's business, including those described in its most recent filing on Form 10-Q.
• Potential for litigation arising from the announcement or existence of the Transaction Agreement.
• The acquisition may be terminated under certain circumstances, including if shareholder approval is not obtained, if the scheme is not effective by the End Date, or if an injunction permanently prohibits consummation.
• Mural may be required to reimburse XOMA Royalty for documented third-party costs and expenses up to 1% of the aggregate consideration if the agreement is terminated under specific circumstances (e.g., a superior proposal or change in recommendation).

Future Outlook

The acquisition is expected to close by the end of 2025, subject to shareholder and High Court approvals. Post-acquisition, XOMA Royalty plans an orderly wind-down of Mural's legacy operations, consolidating corporate functions and disposing of assets, with no assurances for continued employment or benefits for Mural's employees.

Management Comments

• The Transaction Agreement with XOMA Royalty announced today is the result of a thorough and wide-ranging strategic review process, conducted with the support of our legal and financial advisors. We believe that this transaction, which is supported by our Board, achieves the goal of this strategic review process, which was to maximize shareholder value. Caroline Loew, Ph.D., Chief Executive Officer of Mural.
• XOMA Royalty looks forward to working with Mural to close the transaction as soon as possible. Owen Hughes, Chief Executive Officer of XOMA Royalty.

Industry Context

This acquisition reflects a trend in the biotechnology sector where companies with failed clinical programs or limited pipelines seek strategic alternatives, often leading to mergers or acquisitions by entities like royalty aggregators. XOMA Royalty, as a biotechnology royalty aggregator, is acquiring Mural primarily for its cash position and to manage the wind-down of its operations, rather than for its intellectual property or product pipeline, which had recently failed clinical trials. This highlights the challenges faced by clinical-stage biotech companies when their lead assets do not meet endpoints, often resulting in a pivot towards maximizing remaining shareholder value through liquidation or acquisition.

Comparison to Industry Standards

• The premium of 13.1% over the previous day's closing price and 97.6% over the undisturbed price is a significant return for shareholders of a company that recently discontinued all clinical development of its lead asset. For a biotech company whose primary drug candidate failed, a cash acquisition at such a premium, especially compared to the undisturbed price, is generally considered favorable, as the alternative might be a more prolonged and less certain liquidation process.
• The decision to wind down operations and dispose of legacy assets is a common outcome for biotech companies whose clinical programs fail, as maintaining operations without a viable pipeline incurs significant ongoing costs. This approach by XOMA Royalty is consistent with maximizing the remaining cash value.
• The structure of the deal, with a base cash price and a contingent additional payment based on net cash, is a mechanism to provide shareholders with a floor value while allowing for potential upside from efficient wind-down management, which is a reasonable approach in such distressed asset acquisitions.

Management Changes

Corporate Governance

Legal Proceedings

• No specific legal proceedings are detailed as pending or threatened against Mural or its subsidiary that would have a Target Material Adverse Effect.
• The filing mentions potential shareholder litigation related to the transaction, which Mural and Bidder will cooperate in defending or settling.

Related Party Transactions

• Mural Directors, holding approximately 0.42% of outstanding ordinary shares, 1.27% of RSUs, and 4.32% of options, have entered into irrevocable undertakings to vote in favor of the Acquisition.

Stakeholder Impact

• Shareholders: Will receive cash consideration for their shares, with a base price and potential additional payment. This provides liquidity and a premium over recent trading prices, especially given the company's recent clinical setbacks.
• Employees: XOMA Royalty intends to wind down substantially all of Mural's legacy operations, consolidating corporate functions. No assurances are given regarding the continuation of existing compensation and employment benefit arrangements, implying significant job losses. A limited number of employees may be engaged on a consulting basis for the wind-down.
• Customers/Suppliers: Not directly applicable as Mural was a clinical-stage company discontinuing development. The wind-down implies cessation of any existing operational relationships.
• Creditors: Existing contractual obligations and monetary liabilities are factored into the 'Closing Net Cash' calculation, which determines the potential additional price per share.

Next Steps

• Mural will prepare, file, and mail a proxy statement (including the Scheme Document) with the SEC.
• Mural will seek shareholder approval of the Scheme and the Acquisition at a Scheme Meeting and an Extraordinary General Meeting (EGM).
• Mural will make necessary applications to the Irish High Court to sanction the Scheme.
• XOMA Royalty and Sub will participate in the Scheme and be bound by its terms.
• Mural will cause its securities to be delisted from Nasdaq and deregistered under the Exchange Act following the Effective Time.
• Mural will be re-registered as a private company or XOMA Royalty will seek a court-approved reduction of capital.
• XOMA Royalty intends to execute an orderly wind-down of substantially all of Mural's legacy operations promptly following closing.

Key Dates

Recommendation

The acquisition offers a cash exit at a premium to recent trading prices, which is a favorable outcome given the company's recent clinical trial failures and decision to discontinue all development. For existing shareholders, holding until the acquisition closes is advisable to realize the announced cash value. However, there is no further upside beyond the stated cash range, and the additional cash component is uncertain. New investors should exercise caution as the company's operational future is a wind-down, and the stock price will likely trade close to the acquisition price, limiting significant capital appreciation.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Merger, Biotechnology, Immuno-oncology, Scheme of Arrangement, Cash Offer, Shareholder Value, Strategic Review, Clinical Development, Nemvaleukin, Delisting, Wind-down